Mounjaro®-Tirzepatide injection [Japan Edition]

Mounjaro® (Tirzepatide) Injection Pen | Dual GIP/GLP-1 Agonist for Obesity & Metabolic Disease Research

Category: Peptides → Dual Incretin Agonists / Weight Loss / Type 2 Diabetes
Keyphrase: Mounjaro Tirzepatide Injection
Purity: ≥99% (HPLC)
Format: Prefilled Injection Pen
Edition: Japan Edition
Supply Duration: 2 Weeks

🔬 What is Mounjaro® (Tirzepatide)?

Mounjaro®, containing the active peptide Tirzepatide, is a first-in-class dual GIP and GLP-1 receptor agonist. This innovative compound mimics both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), offering synergistic metabolic effects in research related to obesity, type 2 diabetes, and insulin resistance.

The Japan Edition 2-week supply comes in a prefilled injection pen, optimized for subcutaneous delivery in preclinical study models focused on appetite regulation, glucose metabolism, and energy balance.

🧪 Product Specifications

• Synonyms: Tirzepatide, LY3298176

• Molecular Formula: C225H348N48O68

• Molecular Weight: ~4813.5 g/mol

• Form: Prefilled injection pen

• Edition: Japan Research Edition

• Supply Duration: 2 Weeks (typically 2 injections)

• Purity: ≥99% (HPLC)

• Storage: 2–8°C, protect from light

🧬 Key Research Applications

• Obesity & Weight Reduction Models
  Reduces body weight by modulating appetite, fat oxidation, and gastric motility

• Type 2 Diabetes & Insulin Sensitivity Research
  Enhances insulin secretion and sensitivity, reduces fasting glucose, and improves metabolic flexibility

• Incretin Mechanism Studies
  Explores the combined effects of GIP and GLP-1 signaling on beta-cell function and satiety control

• Liver & Cardiovascular Metabolism
  Investigated for its ability to improve lipid profiles, reduce liver fat, and control blood pressure

📚 Selected Scientific References

1. Dual Incretin Receptor Agonism in Obesity Treatment
   New England Journal of Medicine, 2022

2. Tirzepatide and Glucose Regulation
   Diabetes Care, 2021

3. Mechanistic Review of Tirzepatide in T2D Models
   Nature Reviews Drug Discovery, 2022

🔗 Related Research Peptides

• Semaglutide – Long-acting GLP-1 analog for weight loss studies

• Cagrilintide – Amylin analog with synergistic appetite suppression

• Retatrutide – Triple agonist targeting GIP/GLP-1/glucagon receptors

⚠️ For Research Use Only

This product is intended exclusively for laboratory, preclinical, or formulation development use. It is not approved for human use, diagnostics, or therapeutic treatment.